Receptor (biochemistry)

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Retrieved on: 
수요일, 4월 10, 2024
Receptor (biochemistry), Cancer, Safety, Breast, MD, PET/CT, Patient, Neoplasm, MTIC, Therapy, Medical imaging

MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients.

Key Points: 
  • MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients.
  • The Phase 1 dosimetry trial is evaluating the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancer.
  • “The Monopar team is quite excited about this trial initiation,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • We are very much looking forward to seeing the biodistribution and dosimetry data from this first-in-human study in advanced cancer patients.”
    Further information about the MNPR-101-Zr trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Retrieved on: 
목요일, 3월 28, 2024
Cancer, Receptor (biochemistry), Radionuclide, Patient, Neoplasm, PET, G&A, Worldwide Angel, Actinium-225, MTIC, Pancreatic cancer, Investment, Fifth, Therapy, Clinical trial, Safety

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.

Key Points: 
  • WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.
  • Results for the Fourth Quarter and Year Ended December 31, 2023, Compared to the Fourth Quarter and Year Ended December 31, 2022
    Cash, cash equivalents and short-term investments as of December 31, 2023, were $7.3 million.
  • R&D expenses for the fourth quarter of 2023 were $1.0 million compared to $2.1 million for the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 were $0.9 million, compared to $0.8 million for the fourth quarter of 2022.

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Retrieved on: 
화요일, 3월 19, 2024
Receptor (biochemistry), Therapy

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential.

Key Points: 
  • JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential.
  • The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.
  • To participate in the conference call, participants may pre-register here and will receive a dedicated link and dial-in details to easily and quickly access the call.
  • A replay will be available on the InflaRx website in the Investors – Events & Presentations section after the live conference call has concluded.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
목요일, 4월 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
목요일, 4월 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

Retrieved on: 
월요일, 3월 11, 2024
Receptor (biochemistry), DSM-IV codes, FAAN, GAERS, Safety, Society, PO, Generalized tonic–clonic seizure, Therapy, Patient, Epilepsy, Human, Pharmaceutical industry

MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of epilepsy at the American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting on Wednesday, March 13, 2024.

Key Points: 
  • The Company's presentation details are as follows:
    Title: BAER-101, a Selective Potentiator of α2- and α3-containing GABAA Receptors, Fully Suppresses Spontaneous Cortical Spike-Wave Discharges in Genetic Absence Epilepsy
    BAER-101 underwent preclinical in vivo evaluation in SynapCell's GAERS model of absence epilepsy.
  • In the model, BAER-101 demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO.
  • The effect was fast in onset and stable throughout the duration of testing.
  • The combination of safety and tolerability in hundreds of patients and the preclinical efficacy data support BAER-101’s continued development in a Phase 2a trial.

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Retrieved on: 
화요일, 3월 5, 2024
Neoplasm, Actinium-225, SPECT, MD, Radionuclide, Therapy, Receptor (biochemistry), Patient, Radiopharmaceutical, Pancreatic cancer, Cancer, Medical imaging

This is an extension of the tumor imaging and efficacy data Monopar released on February 22 ( link ), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models.

Key Points: 
  • This is an extension of the tumor imaging and efficacy data Monopar released on February 22 ( link ), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models.
  • Two of the most commercially successful radiopharmaceuticals, Pluvicto® and Lutathera™, use the therapeutic radioisotope Lutetium-177 (Lu-177).
  • Monopar collected a sequential SPECT imaging time-series utilizing MNPR-101 conjugated to Lu-177 (MNPR-101-Lu) in a uPAR-expressing human pancreatic cancer xenograft model.
  • “These data further support the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients with uPAR-positive tumors.”

InflaRx Appoints Jan Medina as Head of Investor Relations

Retrieved on: 
목요일, 2월 22, 2024
Therapy, Capital market, Research, CFA, Proteomics, Hematology, Biomedicine, Pyoderma, Biomedical engineering, Receptor (biochemistry), Pharmaceutical industry

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.

Key Points: 
  • JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.
  • Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research.
  • Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We are delighted to welcome Jan to our team.
  • Jan joins InflaRx from Olink Proteomics where he was Vice President, Investor Relations & Capital Markets.

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

Retrieved on: 
목요일, 2월 22, 2024
Neoplasm, Actinium-225, Cancer, Radionuclide, Therapy, Receptor (biochemistry), Patient, Clinical trial, Pancreatic cancer, PET

This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.

Key Points: 
  • This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.
  • Figure 1 below shows the before and after optimization of MNPR-101-Zr, Monopar’s radiopharmaceutical imaging agent for advanced solid tumors expressing uPAR.
  • Preclinical data to date demonstrate compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes.
  • “We are aiming to present these promising preclinical results at an upcoming scientific meeting.”

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Retrieved on: 
화요일, 2월 20, 2024
Actinium-225, MD, Neoplasm, Cancer, PSMA, Safety, Therapy, Receptor (biochemistry), Patient, SSTR2, Clinical trial, PET, Human, Pharmaceutical industry

The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety.

Key Points: 
  • The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety.
  • PET imaging studies in preclinical xenograft models of triple-negative breast, colorectal, and pancreatic cancers displayed high and selective uptake of MNPR-101-Zr in these uPAR-expressing tumors.
  • “This is a significant milestone for Monopar,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • “Following more than 18 months of extensive preclinical development, we believe we are well-positioned in this space.